Melphalan HCl 50mg/vial; pwd for IV infusion after reconstitution and dilution. Melphalan is an alkylating agent with cytotoxic action that appears to be related to the extent of its interstrand ...

Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...

Discover comprehensive details about Melphalan, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Review the side-effects of Melphalan as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Oral melphalan and dexamethasone (MDex ... BMDex was observed in patients without severe (New York Heart Association class III or IV) heart failure and with N-terminal pro-natriuretic peptide ...

Patients who received the three-drug front-line therapy achieved higher response rates and longer time to disease progression than did those who received melphalan and prednisone alone.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan ...

With key upcoming catalysts related to CE Melphalan, Beleodaq and SPI-2012, we continue to be committed to building a world-class Hematology/Oncology company." The phase 2 pivotal trial evaluating ...

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan ...